FindTrial
Sign In

INCB001158

DRUG5 trials

Sponsors

Incyte Corporation, Incyte Biosciences Japan GK

Conditions

Advanced Solid TumorsBiliary Tract Cancer (BTC)Bladder CancerColorectal Cancer (CRC)Endometrial CancerGastric CancerGastroesophageal Cancer (GC)Head and Neck Cancer

Phase 1

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
CompletedNCT02903914
Incyte CorporationBladder Cancer, Colorectal Cancer (CRC), Gastric Cancer +7
Start: 2016-09-14End: 2022-08-15Updated: 2025-08-05
A Phase 1/2 Study of INCB001158 in Combination With Chemotherapy in Subjects With Solid Tumors
CompletedNCT03314935
Incyte CorporationBiliary Tract Cancer (BTC), Colorectal Cancer (CRC), Endometrial Cancer +3
Start: 2017-11-21End: 2022-11-28Updated: 2025-08-12
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
TerminatedNCT03361228
Incyte CorporationSolid Tumors
Start: 2018-03-01End: 2019-03-30Updated: 2020-05-21
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
TerminatedNCT03837509
Incyte CorporationRelapsed or Refractory Multiple Myeloma
Start: 2019-09-25End: 2022-04-05Updated: 2025-11-04
A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid Tumors
CompletedNCT03910530
Incyte Biosciences Japan GKAdvanced Solid Tumors, Metastatic Solid Tumors
Start: 2019-07-22End: 2021-12-14Updated: 2022-02-25

Related Papers

Plasma arginine as a predictive biomarker for outcomes with immune checkpoint inhibition in metastatic colorectal cancer: a correlative analysis of the CCTG CO.26 trial
Journal for ImmunoTherapy of Cancer2024-12-012 citations
Metabolic Reprogramming in Cancer: Implications for Immunosuppressive Microenvironment.
2024-10-2728 citations
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours
BMJ Oncology2024-05-0127 citations
Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.
2023-08-1214 citations
A phase I/II study of safety and efficacy of the arginase inhibitor INCB001158 plus chemotherapy in patients (Pts) with advanced biliary tract cancers.
Journal of Clinical Oncology2021-01-2029 citations
CX-1158-101: A first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients (pts) with solid tumors.
Journal of Clinical Oncology2017-05-2043 citations